The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model

Crathorne?L; Huxley?N; Haasova?M; Snowsill?T; Jones-Hughes?T; Hoyle?M; Briscoe?S; Coelho?H; Long?L; Medina-Lara?A; Mujica-Mota?R; Napier?M; Hyde?C

首页> 外文期刊>Health technology assessment: HTA >The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model

【24h】

The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model

机译：促红细胞生成素促进剂（依泊汀和darbepoetin）在治疗癌症引起的贫血中的有效性和成本效益（包括审查技术鉴定第142号）：系统评价和经济模型

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Health technology assessment: HTA》 |2016年第13期|共页
作者
Crathorne?L; Huxley?N; Haasova?M; Snowsill?T; Jones-Hughes?T; Hoyle?M; Briscoe?S; Coelho?H; Long?L; Medina-Lara?A; Mujica-Mota?R; Napier?M; Hyde?C;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类放射卫生;
关键词

相似文献

外文文献
中文文献

1. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No. 150 and part review of technology appraisal No. 118): a systematic review and economic model [J] . Health technology assessment: HTA . 2013,第14期

机译：一线化疗后西妥昔单抗（单药或联合化疗），贝伐单抗（与非奥沙利铂化疗联合）和帕尼单抗（单药）治疗转移性结直肠癌的临床疗效和成本效益（技术评估编号第150号技术评估和第118号技术评估的部分复审：系统复审和经济模型
2. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of technology appraisal no. 111): A systematic review and Economic model [J] . BondM., RogersG., PetersJ., Health technology assessment: HTA . 2012,第21期

机译：多奈哌齐，加兰他敏，卡巴拉汀和美金刚治疗阿尔茨海默氏病的有效性和成本效益（技术鉴定第111号复审）：系统评价和经济模型
3. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment [J] . Health technology assessment: HTA . 2007,第13期

机译：对与癌症有关的贫血，特别是与癌症治疗有关的贫血中的依泊汀α，依泊汀β和达泊汀α的系统评价和经济评价
4. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model. [O] . Louise Crathorne, Nicola Huxley, Marcela Haasova, -1

机译：促红细胞生成剂（epoetin和darbepoetin）在治疗癌症引起的贫血方面的有效性和成本效益（包括对技术鉴定的审查第142号）：系统的审查和经济模型。
5. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model. [O] . Crathorne, L., Huxley, N., Haasova, M., 2016

机译：红细胞生成刺激剂（epoetin和darbepoetin）治疗癌症治疗诱导的贫血的有效性和成本效益（包括技术评估第142号评论）：系统评价和经济模型。
6. Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment. Comparative Effectiveness Review Number 3 [R] . Seidenfeld, J. 2006

机译：Epoetin和Darbepoetin治疗癌症患者贫血的比较效果。比较效力评论第3号

The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model

著录项

相似文献

相关主题

期刊订阅